Publisher
Springer Science and Business Media LLC
Subject
Pharmacology (medical),Pharmacology
Reference26 articles.
1. European Medicines Agency (EMA). Summary of product characteristics: Cresemba. https://www.ema.europa.eu/en/documents/product-information/cresemba-epar-product-information_en.pdf. Accessed 4 Jul 2023.
2. US Food and Drug Administration. Astellas Pharma Inc. CRESEMBA (isavuconazonium sulfate); 2015. https://www.accessdata.fda.gov/drugsatfda_docs/label/2015/207500Orig1s000lbl.pdf. Accessed 4 Jul 2023.
3. Prattes J, Wauters J, Giacobbe DR, Salmanton-Garcia J, Maertens J, Bourgeois M, et al. Risk factors and outcome of pulmonary aspergillosis in critically ill coronavirus disease 2019 patients-a multinational observational study by the European Confederation of Medical Mycology. Clin Microbiol Infect. 2022;28(4):580–7.
4. Schauwvlieghe A, Rijnders BJA, Philips N, Verwijs R, Vanderbeke L, Van Tienen C, et al. Invasive aspergillosis in patients admitted to the intensive care unit with severe influenza: a retrospective cohort study. Lancet Respir Med. 2018;6(10):782–92.
5. Cornillet A, Camus C, Nimubona S, Gandemer V, Tattevin P, Belleguic C, et al. Comparison of epidemiological, clinical, and biological features of invasive aspergillosis in neutropenic and nonneutropenic patients: a 6-year survey. Clin Infect Dis. 2006;43(5):577–84.
Cited by
2 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献